American Capital Management Inc. Sells 20,462 Shares of Icon Plc $ICLR

American Capital Management Inc. lowered its position in Icon Plc (NASDAQ:ICLR) by 86.2% in the 1st quarter, HoldingsChannel reports. The fund owned 3,270 shares of the medical research company’s stock after selling 20,462 shares during the period. American Capital Management Inc.’s holdings in Icon were worth $362,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Maverick Capital Ltd. purchased a new position in shares of Icon in the first quarter worth about $1,537,000. ABS Direct Equity Fund LLC purchased a new stake in shares of Icon during the 1st quarter valued at approximately $202,000. Rangeley Capital LLC bought a new position in Icon in the 1st quarter worth approximately $1,959,000. Rice Hall James & Associates LLC grew its stake in Icon by 151.8% in the 1st quarter. Rice Hall James & Associates LLC now owns 30,146 shares of the medical research company’s stock valued at $3,336,000 after buying an additional 18,175 shares in the last quarter. Finally, London Co. of Virginia grew its stake in Icon by 93.5% in the 1st quarter. London Co. of Virginia now owns 27,939 shares of the medical research company’s stock valued at $3,092,000 after buying an additional 13,501 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Barclays lifted their price target on Icon from $160.00 to $175.00 and gave the company an “equal weight” rating in a research report on Thursday, June 25th. Robert W. Baird raised their target price on Icon from $168.00 to $186.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Weiss Ratings lowered Icon from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, May 29th. Citigroup upped their price target on Icon from $140.00 to $165.00 and gave the company a “neutral” rating in a research report on Thursday, June 25th. Finally, Mizuho increased their price target on shares of Icon from $180.00 to $190.00 and gave the stock an “outperform” rating in a report on Friday, June 26th. Seven equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, Icon presently has an average rating of “Hold” and a consensus target price of $168.73.

Icon Stock Performance

NASDAQ ICLR opened at $168.78 on Tuesday. The company has a 50-day simple moving average of $152.21 and a two-hundred day simple moving average of $135.77. Icon Plc has a 12-month low of $66.57 and a 12-month high of $203.91. The firm has a market cap of $12.92 billion, a price-to-earnings ratio of 30.03, a PEG ratio of 8.14 and a beta of 1.22. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 0.31.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.